#USA #Portland #Rehabilitation #MedRhythms #InTandem

MedRhythms' InTandem® Rehabilitation System Gains Medicare Coverage

On January 16, 2025, MedRhythms, Inc. announced a significant milestone regarding its flagship product, the InTandem® rehabilitation system. The Centers for Medicare and Medicaid Services (CMS) approved a final pricing determination, allowing for capped rental payments under Medicare for this innovative therapy device. Effective April 1, 2025, this decision marks a critical advancement in ensuring accessibility for patients suffering from chronic stroke-related gait impairments.

What is InTandem®?

InTandem® is designed to deliver progressive rhythmic auditory stimulation (RAS) therapy. This therapy is pivotal in enhancing walking quality and speed, essential for improving health outcomes and reducing the risk of complications common in post-stroke patients. The system comprises wearable, clinical-grade gait sensors and a hardware control unit that utilizes sophisticated adaptive algorithms, paired with clinically optimized music to automate the key principles of RAS therapy.

Brian Harris, CEO and Co-Founder of MedRhythms, expressed, "We founded MedRhythms and developed InTandem to introduce an innovative device that aids people with chronic stroke walking impairments. Securing this milestone is vital in ensuring that those in need can readily access InTandem's benefits. We are grateful to CMS for this decision."

The Significance of Medicare Coverage

The approval emphasizes the importance of Medicare's commitment to enhancing the lives of patients in need of rehabilitation technologies. With the establishment of the new Healthcare Common Procedure Coding System (HCPCS) code E3200 specifically for InTandem, the system now falls under the durable medical equipment (DME) category for Medicare benefits.

As it stands, Medicare payments will rely on commercial pricing for InTandem, effectively making this vital service accessible to a broader range of patients living with chronic conditions.

The system's self-guided features allow users to engage with evidence-based therapeutic interventions from the comfort of their homes. This reshapes traditional rehabilitation practices by providing patients with tools and support for ongoing recovery.

Intended Use and Indications

InTandem is intended for the rehabilitation of ambulatory adults recovering from chronic stroke, significantly improving their walking and ambulation capabilities. The growing body of evidence surrounding the efficacy and safety of this innovative technology bolsters its role in contemporary healthcare practices.

Clinicians, caregivers, and insurers are encouraged to explore more about InTandem at www.intandemrx.com, where they can also check eligibility and schedule personal information sessions.

About MedRhythms

MedRhythms is at the forefront of developing next-generation neurotherapeutics that improve mobility outcomes through patented technologies combining sensors, software, and music with advanced neuroscience. Their commitment extends across various neurological conditions, including stroke, multiple sclerosis, and Parkinson's disease.

Established in Portland, Maine, MedRhythms has made significant strides in its mission to improve the quality of life for individuals affected by these conditions. Their partnership with Universal Music Group in 2021 and subsequent funding have propelled their innovative endeavors forward.

For more information on the company and its products, visit www.medrhythms.com.

With the new Medicare coverage in place, InTandem is set to revolutionize rehabilitation for stroke survivors, paving the way for greater independence and improved health outcomes.